FDA Approves New Eye Pressure Drop Formulation

WASHINGTON (MedPage Today) — The FDA approved a new formulation of the drug bimatoprost (Lumigan) in a 0.01% solution as a first-line treatment to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Researchers complete INX-189 clinical trials for Hepatitis C virus

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

AVAC calls for economic and political support for CAPRISA 004 microbicide trial’s critical follow-up studies

AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon [...]

Forecasting: Patient Flow Modeling Comes Of Age - Pre-Summit Workshop October 5th Boston

Judith Kulich, Associate Principal, and Emily Jin, Manager, at ZS Associates talk to eyeforpharma about how patient flow modeling can inform forecasting. Patient flow, or system dynamics forecasting is a common approach for modeling situations in which patient potential is affected by movement between disease states…

ForteBio Announces Launch Of Protein G Biosensor For Use On Company’s Octet® Instruments

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution…

Medical Affairs Report Outlines Resource Needs For Group Success

The Medical Affairs function arguably plays the most critical role in a biopharmaceutical organization, with heavy responsibilities across areas such as clinical development, scientific publications, KOL development, and medical education. These areas must operate effectively for new products to succeed…

Almost half of all Americans use prescription drugs each month

Nearly half of all Americans used at least one prescription drug per month in 2008, according to a study by the Centers for Disease Control and Prevention, Bloomberg reports. That’s a 10 percent increase over the preceding decade. Over that time, yearly spending by Americans on drugs doubled to $234 billion. “The two biggest-sellers last [...]

FDA approves IDE study to evaluate HeartWare Ventricular Assist System

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a second allotment of 54 patients in its “ADVANCE” bridge-to-transplant [...]

Tigecycline Label to Warn on Increased Death Risk

(MedPage Today) — A warning that the intravenous antibiotic drug tigecycline (Tygacil) is associated with increased risk of death, compared with other antibiotics, will be added to the product’s label, the FDA said.

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company’s accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges [...]